OVCAR-3、SKOV-3 和 A2780 珍珠棉系的增殖和克隆形成活性受到盐酸米诺环素（0-100 μM，24-72 小时）的抑制 [3]。米诺环素盐酸盐（0-100 μM，24-48 小时）。在示波器中，盐酸米诺环素（0-100 μM，72 小时））会引起细胞周期 [3]。除了抑制 caspase 依赖性和 caspase 非依赖性细胞死亡外，直接神经保护还可能与线粒体异常和细胞色素 c 保护有关 [2]。盐酸米诺环素诱导缺氧诱导因子（HIF）细胞增殖的检测[3]

在雌性裸鼠中，每天一次静脉注射盐酸卵分泌素（0-30 mg/kg），持续四个星期，可抑制 OVCAR-3 肿瘤的生长[3]。在脑损伤动物模型中，盐酸米诺环素 (IP) 是一种强效药物，在腹腔内高剂量给药时表现出神经保护作用 [1]。盐酸米诺环素（0-40 mg/kg，IP，一次）可显着抑制 METH 诱导的小鼠过度运动和行为敏化 [2]。在暂时性大脑中动脉闭塞 (TMCAO) 模型中，盐酸米诺环素（静脉注射 3 和 10 mg/kg 一次）可有效减少梗塞面积 [1]。盐酸米诺环素（3-10 mg/kg，静脉注射一次）对血液的影响可能会因电位诱发的室性心律失常而减轻。标准 200 mg 剂量对人体的这种作用可能与线粒体 KATP 通道、PI3K/Akt 信号传导和 L 型水平 (3 mg/kg) 有关[1]。

细胞增殖检测[3]
细胞类型：人卵巢癌细胞系（OVCAR-1α抑制，以及up-p53蛋白和AKT水平的调节/mTOR/p70S6K/4E-BP1失活染料 [6]。3. SKOV-3 和 A2780）和原代细胞（HEK-293、HMEC、HUVEC、ATCC）
测试浓度：0、1、10、50 和 100 μM
孵育时间：24、48或72小时
实验结果：抑制OVCAR-3、SKOV-3的增殖和A2780细胞呈浓度依赖性，IC50值分别为62.0、56.1和59.5 μM。对 HEK-293 或 HUVEC 的活力没有影响。

---

蛋白质印迹分析[3]
细胞类型： OVCAR-3、SKOV-3 和 A2780 细胞
测试浓度： 0、 10、50 和 100 μM
孵育时间：72 小时
实验结果： Cyclins A、B 和 E 低表达水平。 caspase- 增加 3 个水平，在 100 μM 时增加超过 3.0 倍。米诺环素激活的 caspase-3 进而导致 PARP-1 的裂解。 Caspase-3 增加 PARP-1、p89 的降解产物。

---

细胞周期分析[3]
细胞类型： OVCAR-3、SKOV-3 和 A2

Animal/Disease Models: Female nude mice (6 weeks old, 9 mice per group, each mouse was injected with OVCAR-3 cells subcutaneously (sc) (sc) on the left side of the abdomen) [3]
Doses: 10 or 30 mg/kg
Route of Administration: Orally in drinking water Administration, starting on day 8 of cell inoculation, one time/day for 4 weeks.
Experimental Results: Inhibited OVCAR-3 tumor growth and diminished microvessel density in these female nude mice.

---

Animal/Disease Models: Male Balb/cAnNCrICrIj mice (8 weeks old, 23-30 g, methamphetamine (METH, 3 mg/kg) subcutaneously (sc) (sc) (sc) in a volume of 10 ml/kg) [2]
Doses: 0, 10 , 20 or 40 mg/kg
Route of Administration: intraperitoneal (ip) injection, once, 30 minutes before METH administration
Experimental Results: Significantly attenuated METH-induced hyperlocomotion and the development of behavioral sensitization in mice at 40 mg/kg. Did not exert any effect on the induction of METH-induced hyperthermia in mice. Significantly attenuated the reduction of DA and DOPAC in the striatum. Significantly attenuated the reduction of DAT-immunoreactivity in the mouse striatum. Significantly attenuated the increase in MAC1-immunoreactivity in the striatum after the administration of METH.

---

Animal/Disease Models: Male Sprague-Dawley rats (270-330 g, TMCAO model)[1]
Doses: 3 mg/kg and 10 mg/kg
Route of Administration: IV, once, 4, 5, or 6 hours post TMCAO
Experimental Results: Reduced infarct size by 42% while 10 mg/kg reduced infarct size by 56% at doses of 3 mg/kg; significantly reduced infarct size at 5 hours by 40% at doses of 10 mg/kg and the 3 mg/kg dose significantly reduced infarct size by 34%. With a 6 hour time window there was a non-significant trend in infarct reduction.

---

Animal/Disease Models: Male Sprague-Dawley rats (270-330 g)[1]
Doses: 3, 10, or 20 mg/kg
Route of Administration: IV, once
Experimental Results: Peak concentrations of serum levels of minocycline averaged 3.6, 13.0 and 28.8 mg/L with 3, 10 and 20 mg/kg doses respectively. The serum levels of minocycline at a 3 mg/kg dose (3.6 mg/L) were similar to that reported in humans after a standard 200 mg dose. Did not significantly affect hemodynamic and physiological variables.

[1]. Xu L, et al. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol. 2004 Apr 26;4:7.
[2]. Zhang L, et al. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1381-93.
[3]. Pourgholami MH, et al. Minocycline inhibits growth of epithelial ovarian cancer. Gynecol Oncol. 2012 May;125(2):433-40.
[4]. Molina-Hernández M, et al. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):380-6.
[5]. Ritchie DJ, et al. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S374-80.
[6]. Ataie-Kachoie P, et al. Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. Am J Cancer Res. 2015 Jan 15;5(2):575-88.
[7]. Hu X, Wu B, Wang X, Xu C, He B, Cui B, Lu Z, Jiang H. Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. Eur J Pharmacol. 2011 Mar 11;654(3):274-9.

C23H28CLN3O7

493.9373

13614-98-7

Minocycline;10118-90-8

O=C([C@@]1(O)[C@@](C[C@]2([H])C(C1=O)=C(O)C3=C(O)C=CC(N(C)C)=C3C2)([H])[C@@H]4N(C)C)/C(C4=O)=C(N)/O.[H]Cl

KDLQIOPKJDNQIM-YKWOUSISSA-N

InChI=1S/C23H27N3O7.ClH/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28;/h5-6,9,11,17,27-28,32-33H,7-8,24H2,1-4H3;1H/b22-16+;/t9-,11-,17+,23-;/m1./s1

(4S,4aR,5aS,12aR,E)-2-(amino(hydroxy)methylene)-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5a,6,12a-tetrahydrotetracene-1,3,12(2H,4H,5H)-trione hydrochloride

NSC 141993; Minocycline HCl; NSC 141993; Mynocine hydrochloride; NSC141993; NSC-141993; Periocline; Klinomycin; Minocin; Solodyn; Mynocine; Tri-mino; Vectrin; Ximino; Minomax; Minomycin chloride; Mynocine hydrochloride

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ~19.23 mg/mL (~38.93 mM)
H2O : ~9.09 mg/mL (~18.40 mM)

Solubility in Formulation 1: 7.69 mg/mL (15.57 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。